Interferon-β 1a and SARS Coronavirus Replication

A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort...

Descripción completa

Detalles Bibliográficos
Autores principales: Hensley, Lisa E., Fritz, Elizabeth A., Jahrling, Peter B., Karp, Christopher, Huggins, John W., Geisbert, Thomas W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2004
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322919/
https://www.ncbi.nlm.nih.gov/pubmed/15030704
http://dx.doi.org/10.3201/eid1002.030482
_version_ 1782229117745233920
author Hensley, Lisa E.
Fritz, Elizabeth A.
Jahrling, Peter B.
Karp, Christopher
Huggins, John W.
Geisbert, Thomas W.
author_facet Hensley, Lisa E.
Fritz, Elizabeth A.
Jahrling, Peter B.
Karp, Christopher
Huggins, John W.
Geisbert, Thomas W.
author_sort Hensley, Lisa E.
collection PubMed
description A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon (IFN)-β 1a potently inhibits SARS coronavirus replication in vitro.
format Online
Article
Text
id pubmed-3322919
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-33229192012-04-17 Interferon-β 1a and SARS Coronavirus Replication Hensley, Lisa E. Fritz, Elizabeth A. Jahrling, Peter B. Karp, Christopher Huggins, John W. Geisbert, Thomas W. Emerg Infect Dis Research A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon (IFN)-β 1a potently inhibits SARS coronavirus replication in vitro. Centers for Disease Control and Prevention 2004-02 /pmc/articles/PMC3322919/ /pubmed/15030704 http://dx.doi.org/10.3201/eid1002.030482 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Hensley, Lisa E.
Fritz, Elizabeth A.
Jahrling, Peter B.
Karp, Christopher
Huggins, John W.
Geisbert, Thomas W.
Interferon-β 1a and SARS Coronavirus Replication
title Interferon-β 1a and SARS Coronavirus Replication
title_full Interferon-β 1a and SARS Coronavirus Replication
title_fullStr Interferon-β 1a and SARS Coronavirus Replication
title_full_unstemmed Interferon-β 1a and SARS Coronavirus Replication
title_short Interferon-β 1a and SARS Coronavirus Replication
title_sort interferon-β 1a and sars coronavirus replication
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322919/
https://www.ncbi.nlm.nih.gov/pubmed/15030704
http://dx.doi.org/10.3201/eid1002.030482
work_keys_str_mv AT hensleylisae interferonb1aandsarscoronavirusreplication
AT fritzelizabetha interferonb1aandsarscoronavirusreplication
AT jahrlingpeterb interferonb1aandsarscoronavirusreplication
AT karpchristopher interferonb1aandsarscoronavirusreplication
AT hugginsjohnw interferonb1aandsarscoronavirusreplication
AT geisbertthomasw interferonb1aandsarscoronavirusreplication

Ejemplares similares